Cartesian updates Descartes-08 pipeline; IND accepted in myositis, pediatric trial initiated

Cartesian Therapeutics, Inc.

Phase 3 AURORA trial for Descartes-08 in myasthenia gravis enrollment on track; data expected to support cash runway into mid-2027.
FDA accepted IND for Descartes-08 in myositis; seamless adaptive Phase 2 TRITON trial expected to start 1H26.
Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomyositis initiated.
Two Nature Medicine publications; Phase 2b MG data showed 55% median prednisone dose reduction at Month 12, no CRS or ICANS.
Cash resources expected to fund operations including Phase 3 trial completion through mid-2027.

item 7.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001453687-26-000051
form_type: 8-K
ticker: RNAC
cik: 0001453687
company_name: Cartesian Therapeutics, Inc.
filed_at: 2026-01-09T23:59:59+00:00
discovered_at: 2026-05-14T18:02:35.112695+00:00
generated_at: 2026-05-16T11:03:03.284308+00:00
sec_items: ["7.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.65
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001453687-26-000051
json_url: https://secwatch.observer/filing/0001453687-26-000051.json
markdown_url: https://secwatch.observer/filing/0001453687-26-000051.md
text_url: https://secwatch.observer/filing/0001453687-26-000051.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000051/0001453687-26-000051-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1453687/000145368726000051/rnac-20260109.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001453687-26-000051

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.